Federated Hermes’s 4D Molecular Therapeutics FDMT Stock Holding History

Federated Hermes’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.96M	Sell	222,416 -1,209,844	-84%	-$11.8M	﹤0.01%	946
2026 Q1	$13.3M	Sell	1,432,260 -177,222	-11%	-$1.54M	0.02%	566
2025 Q4	$12.1M	Buy	1,609,482 +14,650	+0.9%	+$149K	0.02%	567
2025 Q3	$13.9M	Sell	1,594,832 -72,506	-4%	-$433K	0.02%	495
2025 Q2	$6.19M	Buy	1,667,338 +417,157	+33%	+$1.47M	0.01%	670
2025 Q1	$4.04M	Buy	1,250,181 +1,246,419	+33,132%	+$5.87M	0.01%	761
2024 Q4	$21K	Buy	+3,762	New	+$29.5K	﹤0.01%	1765
2024 Q2	–	Sell	-27	Closed	-$860	–	2054
2024 Q1	$860	Buy	+27	New	+$689	﹤0.01%	1965
2022 Q3	–	Sell	-219	Closed	-$2K	–	2171
2022 Q2	$2K	Buy	+219	New	+$2.13K	﹤0.01%	1975
2021 Q3	–	Sell	-4,200	Closed	-$101K	–	2250
2021 Q2	$101K	Sell	4,200 -145,800	-97%	-$4.46M	﹤0.01%	1789
2021 Q1	$6.51M	Hold	150,000	–	–	0.01%	775
2020 Q4	$6.22M	Buy	+150,000	New	+$6.19M	0.01%	751

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Federated Hermes's FDMT Position: Q2 2026 in Review

Federated Hermes reduced its 4D Molecular Therapeutics (FDMT) stake by 84% in Q2 2026, selling an estimated $11.8M and leaving 222,416 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Federated Hermes first reported a position in FDMT in Q4 2020 and has held it in 12 quarters since. The position peaked at $13.9M in Q3 2025. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Federated Hermes held 222,416 shares of 4D Molecular Therapeutics worth $2.96M as of Q2 2026.
Federated Hermes sold 1,209,844 4D Molecular Therapeutics shares in Q2 2026, an estimated $11.8M.
4D Molecular Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #946 holding.
Federated Hermes first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 12 quarters since.
Federated Hermes's 4D Molecular Therapeutics position peaked at $13.9M in Q3 2025.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.